Bruker Corporation (BRKR)
NASDAQ:BRKR
Want to see BRKR full AI Analyst Report?
Top Page
Bruker
(NASDAQ:BRKR)
Select Model
Select Model
Rating:62Neutral
Price Target:
$47.00
▲(15.48% Upside)
Action:Reiterated
Date:05/22/26
The score is driven primarily by mixed financial performance: strong revenue growth but materially weaker profitability and returns, with cash flow still positive. Technicals are supportive with clear positive trend and momentum. This is held back by a very expensive valuation (high P/E, low yield), while the latest earnings call adds modest support via reconfirmed guidance, above-target cost savings, and strong bookings despite near-term organic and margin headwinds.
Positive Factors
Sustained Revenue Growth & Diverse Revenue Mix
Multi-year top-line expansion combined with a mix of instruments, services, consumables and software creates durable revenue diversity. Capital equipment cycles drive high-ticket sales while recurring service/consumable streams smooth volatility and support predictable aftermarket cash flows.
Negative Factors
Profitability Reset and Compressed Margins
Earnings and returns have fallen from prior peaks, indicating structural margin pressure from mix, lower volumes, and cost carry. Persistent low operating margins reduce reinvestment capacity and raise execution risk if top-line momentum falters, limiting durable returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth & Diverse Revenue Mix
Multi-year top-line expansion combined with a mix of instruments, services, consumables and software creates durable revenue diversity. Capital equipment cycles drive high-ticket sales while recurring service/consumable streams smooth volatility and support predictable aftermarket cash flows.
Read all positive factors
Bruker (BRKR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.96B
Dividend Yield0.42%
Average Volume (3M)2.24M
Price to Earnings (P/E)95.4
Beta (1Y)1.24
Revenue Growth0.36%
EPS Growth-145.55%
CountryUS
Employees11,396
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.24
Shares Outstanding152,225,620
10 Day Avg. Volume2,597,845
30 Day Avg. Volume2,244,256
Financial Highlights & Ratios
PEG Ratio6.94
Price to Book (P/B)2.91
Price to Sales (P/S)2.08
P/FCF Ratio165.16
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue2.46
Enterprise Value/Gross Profit5.39
Enterprise Value/Ebitda26.77
Forecast
1Y Price Target
$47.00Price Target Upside15.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)2.12
Revenue Forecast (FY)$3.59B
Bruker Business Overview & Revenue Model
Company Description
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) L...
How the Company Makes Money
Bruker primarily makes money by selling scientific instruments and integrated analytical systems, complemented by recurring revenue from services, software, and consumables. Key revenue streams typically include: (1) Instrument and system sales: O...
Bruker Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call presents a cautiously constructive picture: management beat Q1 expectations, highlighted multiple high-growth, AI-driven and idiosyncratic end-market opportunities (Semi Metrology, SciY, security detection, BEST superconductors), and is delivering cost savings above original targets while reconfirming full-year guidance. These positives are balanced against meaningful near-term organic revenue declines, China and academic funding weaknesses, margin and mix pressures, and EPS softening in Q1. On balance, the positive operational momentum (strong bookings, large multi-year orders, and expanded cost savings) and reconfirmed guidance slightly outweigh the current headwinds.Positive Updates
Reported Revenue Beat
Q1 reported revenue $823.4M, up 2.7% year-over-year (FX tailwind +4.5%, M&A +2.6%, organic -4.4%) and came in ahead of prior expectations.
Negative Updates
Organic Revenue Decline
Q1 organic revenue decreased 4.4% year-over-year; BSI segment revenues down ~5% organically and BioSpin CER revenue declined in the high-single-digits.
Read all updates
Q1-2026 Updates
Positive
Negative
Reported Revenue Beat
Q1 reported revenue $823.4M, up 2.7% year-over-year (FX tailwind +4.5%, M&A +2.6%, organic -4.4%) and came in ahead of prior expectations.
Read all positive updates
Company Guidance
Bruker reconfirmed its full‑year 2026 guidance: reported revenue $3.57B–$3.60B (reported growth 4%–5% vs FY25) with organic revenue growth of 1%–2%, acquisitions contributing ~1.5% and an estimated FX tailwind of ~1.5%; it expects organic non‑GAAP operating margin expansion of 300–350 bps (netting to a 250–300 bps improvement vs FY25’s 12.6% after an ~50 bp FX headwind) and non‑GAAP EPS of $2.10–$2.15 (15%–17% reported growth; an ~8% FX headwind implies CER EPS growth of 23%–25%). Management said Q2 should return to organic revenue growth (low‑ to mid‑single digits) with a meaningful sequential step‑up in non‑GAAP operating margin and EPS as tariff/FX laps ease, citing Q1 as a strong start (Q1 revenue $823.4M, +2.7% reported; organic –4.4%; M&A +2.6%; FX +4.5%; BSI organic bookings high‑single‑digits; BSI book‑to‑bill >1.0x) and Q1 non‑GAAP gross and operating margins of 50% and 10.2%, Q1 non‑GAAP EPS $0.31, while tracking roughly $140M of annualized cost savings (up from a $100–120M target).Bruker Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
62
Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.46B | 3.44B | 3.37B | 2.96B | 2.53B | 2.42B |
| Gross Profit | 1.58B | 1.58B | 1.65B | 1.51B | 1.31B | 1.21B |
| EBITDA | 317.30M | 302.60M | 438.60M | 675.50M | 518.70M | 497.10M |
| Net Income | -11.60M | -8.60M | 113.10M | 427.20M | 296.60M | 277.10M |
Balance Sheet | ||||||
| Total Assets | 6.13B | 6.24B | 5.81B | 4.25B | 3.61B | 3.65B |
| Cash, Cash Equivalents and Short-Term Investments | 133.40M | 298.80M | 183.40M | 488.30M | 645.50M | 1.17B |
| Total Debt | 1.67B | 2.04B | 2.25B | 1.38B | 1.27B | 1.39B |
| Total Liabilities | 3.63B | 3.73B | 3.99B | 2.84B | 2.48B | 2.57B |
| Stockholders Equity | 2.45B | 2.46B | 1.78B | 1.38B | 1.11B | 1.07B |
Cash Flow | ||||||
| Free Cash Flow | 51.30M | 43.30M | 136.00M | 243.20M | 145.20M | 190.40M |
| Operating Cash Flow | 140.30M | 134.10M | 251.30M | 350.10M | 274.40M | 282.40M |
| Investing Cash Flow | -210.10M | -196.50M | -1.76B | -326.00M | -251.60M | -192.40M |
| Financing Cash Flow | -18.60M | 135.10M | 1.23B | -193.40M | -415.30M | 318.70M |
Bruker Technical Analysis
Positive
40.70
Price Trends
38.46
Positive
41.19
Positive
39.76
Positive
Market Momentum
1.79
Negative
66.92
Neutral
86.98
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRKR, the sentiment is Positive. The current price of 40.7 is below the 20-day moving average (MA) of 41.22, above the 50-day MA of 38.46, and above the 200-day MA of 39.76, indicating a bullish trend. The MACD of 1.79 indicates Negative momentum. The RSI at 66.92 is Neutral, neither overbought nor oversold. The STOCH value of 86.98 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BRKR.
Bruker Risk Analysis
Bruker disclosed 42 risk factors in its most recent earnings report. Bruker reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bruker Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $11.51B | 23.46 | 13.04% | ― | 23.49% | 219.12% | |
72 Outperform | $4.06B | 38.98 | 9.13% | ― | 12.40% | ― | |
66 Neutral | $7.75B | -3.56 | 2.40% | ― | 1.92% | ― | |
62 Neutral | $6.96B | 95.44 | -0.51% | 0.42% | 0.36% | -145.55% | |
61 Neutral | $3.03B | 45.09 | 8.23% | ― | 5.48% | 77.43% | |
52 Neutral | $7.06B | -78.94 | -26.46% | ― | 36.30% | -42.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
BRKR
Bruker
45.69
10.38
29.40%
BIO
Bio-Rad Laboratories
287.74
63.96
28.58%
ITGR
Integer Holdings
89.28
-29.03
-24.54%
GMED
Globus Medical
84.81
25.85
43.84%
GKOS
Glaukos
120.23
24.21
25.21%
LIVN
LivaNova
73.83
31.95
76.29%
Bruker Corporate Events
Executive/Board ChangesShareholder Meetings
Bruker Shareholders Reelect Directors and Approve Governance Items
Positive
May 21, 2026
At its 2026 Annual Meeting of Stockholders held on May 21, 2026, Bruker Corporation’s shareholders elected Laura A. Francis, John J. (Jack) Phillips and Hermann F. Requardt, Ph.D. as Class II directors to serve three-year terms ending at the...
Dividends
Bruker Declares Quarterly Cash Dividend, Signaling Ongoing Confidence
Positive
May 15, 2026
On May 14, 2026, Bruker Corporation’s board of directors declared a quarterly cash dividend of $0.05 per share on its common stock, with a par value of $0.01 per share. The dividend is scheduled to be paid on July 7, 2026, to shareholders of...
Dividends
Bruker Declares Quarterly Dividend on Preferred Stock
Positive
Apr 28, 2026
Bruker Corporation announced that its Board of Directors declared a quarterly cash dividend on the company’s 6.375% Mandatory Convertible Preferred Stock, Series A, of $3.9844 per share. The dividend was declared on April 28, 2026, and is pa...
Executive/Board Changes
Bruker Announces Planned Transition of BioSpin Group President
Neutral
Apr 10, 2026
On April 6, 2026, Bruker Corporation and Falko Busse, Ph.D., President of its Bruker BioSpin Group, agreed that his executive duties would begin transitioning around May 1, 2026, with his employment at Bruker and Bruker BioSpin ending on October 3...
Business Operations and StrategyExecutive/Board Changes
Bruker Expands Board, Appoints Thierry Bernard as Director
Positive
Apr 1, 2026
On March 27, 2026, Bruker’s board voted to expand its size to 12 members and appointed Thierry L. Bernard, CEO and Managing Director of QIAGEN N.V., as a Class III director effective April 1, 2026, with a term running until the 2027 annual m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.